Karhla

Drospirenone, the active ingredient in Karhla, is a combined estrogen‑progestogen oral contraceptive presented as a combined oral tablet for oral use. It is used to prevent pregnancy and to help regulate menstrual cycles in women of reproductive age.

GNH USA supplies Karhla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Karhla, a combined estrogen‑progestogen oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy and manage menstrual disorders.

- Prevention of pregnancy: suppresses ovulation and creates an inhospitable cervical environment. - Regulation of menstrual cycles: reduces irregular bleeding and stabilises cycle length. - Management of moderate acne: decreases androgen‑driven sebum production, improving skin lesions.

Karhla may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Spotting: irregular light bleeding between periods. - Mood changes: irritability or mild depressive symptoms. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident due to clot or hemorrhage. - Myocardial infarction: heart attack from coronary blockage. - Severe hypertension: sudden, high blood pressure elevation. - Liver disorders: jaundice or hepatic dysfunction.

Before prescribing Karhla, clinicians should evaluate individual risk factors and contraindications.

- Assess thromboembolic risk: review personal and family history of clotting disorders. - Evaluate cardiovascular health: consider hypertension, smoking status, and age. - Screen for liver disease: avoid use in active hepatic impairment. - Consider migraine history: contraindicated in patients with migraine with aura. - Review medication list: identify potential drug interactions. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Karhla can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Selective serotonin reuptake inhibitors: may heighten risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., phenytoin): may modestly decrease hormone levels. - St. John’s wort: herbal supplement that can lower contraceptive effectiveness. - Certain antibiotics (e.g., tetracycline): may have minimal impact but require observation.